CML
MCID: LKM068
MIFTS: 68

Leukemia, Chronic Myeloid, Somatic (CML) malady

Categories: Genetic diseases, Rare diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia, Chronic Myeloid, Somatic

Aliases & Descriptions for Leukemia, Chronic Myeloid, Somatic:

Name: Leukemia, Chronic Myeloid, Somatic 54 38
Chronic Myelogenous Leukemia 12 50 25 56 66 29 14
Chronic Myeloid Leukemia 38 12 50 25 56 41 14
Cml 12 50 25 56 66
Chronic Granulocytic Leukemia 12 50 25 56
Leukemia, Chronic Myeloid 54 50 66 13
Myeloid Leukemia, Chronic 12 29 69
Leukemia, Chronic Myeloid, Atypical 66 29
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 69
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 66
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive 42
Cml - Chronic Myelogenous Leukemia 12
Chronic Myelocytic Leukemia 25
Myeloid Leukemia Chronic 52
Acml 66
Cgl 25

Characteristics:

Orphanet epidemiological data:

56
chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

HPO:

32
leukemia, chronic myeloid, somatic:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 608232
Disease Ontology 12 DOID:8552
ICD9CM 35 205.1
MeSH 42 D015464
NCIt 47 C3174
Orphanet 56 ORPHA521
UMLS via Orphanet 70 C0023473
ICD10 via Orphanet 34 C92.1
UMLS 69 C0023473

Summaries for Leukemia, Chronic Myeloid, Somatic

MedlinePlus : 41 leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in chronic myeloid leukemia (cml), there are too many granulocytes, a type of white blood cell. most people with cml have a gene mutation (change) called the philadelphia chromosome. sometimes cml does not cause any symptoms. if you have symptoms, they may include: fatigue weight loss night sweats fever pain or a feeling of fullness below the ribs on the left side tests that examine the blood and bone marrow diagnose cml. treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Leukemia, Chronic Myeloid, Somatic, also known as chronic myelogenous leukemia, is related to myeloproliferative neoplasm and atypical chronic myeloid leukemia, and has symptoms including fatigue, fever and splenomegaly. An important gene associated with Leukemia, Chronic Myeloid, Somatic is BCR (BCR, RhoGEF And GTPase Activating Protein), and among its related pathways/superpathways are Chronic myeloid leukemia and Innate Immune System. The drugs Bosulif and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and hematopoietic system

Disease Ontology : 12 A myeloid leukemia that is characterized by over production of white blood cells.

Genetics Home Reference : 25 Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.

UniProtKB/Swiss-Prot : 66 Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Description from OMIM: 608232

Related Diseases for Leukemia, Chronic Myeloid, Somatic

Diseases in the Leukemia, Chronic Myeloid, Somatic family:

Acute Myeloid Leukemia, Somatic Dnmt3a-Related

Diseases related to Leukemia, Chronic Myeloid, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 32.5 CSF3 JAK2 RUNX1
2 atypical chronic myeloid leukemia 12.4
3 familial chronic myelocytic leukemia-like syndrome 12.3
4 chronic myelocytic leukemia 12.2
5 philadelphia-negative chronic myeloid leukemia 12.1
6 leukemia 11.3
7 lipodystrophy, congenital generalized, type 1 10.8
8 lipodystrophy, congenital generalized, type 2 10.8
9 pigmented purpuric dermatosis 10.4 ABL1 BCR
10 unilateral hemispheric polymicrogyria 10.4 FLT3 KIT RUNX1
11 acute respiratory distress syndrome 10.4 FLT3 JAK2 KIT
12 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.4 JAK2 PDGFRA PDGFRB
13 cytokine receptor deficiency 10.4 CSF2 IL3 KITLG
14 spondylocostal dysostosis 2 10.4 IFNA2 JAK2 SETBP1
15 dfnb1 10.4 KIT PDGFRA PDGFRB
16 chondrodysplasia punctata, tibia-metacarpal type 10.4 BCR IFNA1 IFNA2
17 von hippel anomaly 10.4 IL3 JAK2 RUNX1
18 febrile seizures, familial, 2 10.4 CSF2 CSF3 IL3
19 choledochal cyst 10.4 CSF2 IL3
20 uremic neuropathy 10.4 KIT KITLG PDGFRA
21 agammaglobulinemia 8, autosomal dominant 10.4 FLT3 JAK2 KIT
22 mental retardation, autosomal dominant 37 10.4 CSF2 CSF3 IL3
23 malignant epithelial mesothelioma 10.4 IFNA2 KIT PDGFRA
24 eosinophilic cystitis 10.4 CSF2 CSF3 IFNA1
25 hemangioma of peripheral nerve 10.4 IFNA2 KIT KITLG
26 scleroderma, familial progressive 10.4 CSF2 CSF3 IL3
27 adducted thumbs dundar type 10.4 FLT3 KIT RUNX1
28 olfactory nerve disease 10.4 KIT KITLG PDGFRA
29 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 10.4 IL3 JAK2 STAT5A
30 middle cerebral artery infarction 10.4 CSF2 IL3 KITLG RUNX1
31 kahrizi syndrome 10.4 IL3 KIT PDGFRA PDGFRB
32 myofibromatosis, infantile, 1 10.4 IFNA2 PDGFRB
33 arteriosclerosis obliterans 10.4 ABL1 PDGFRB
34 bifid uvula 10.4 ABL1 BCR FLT3
35 congenital disorder of glycosylation, type iq 10.4 IFNA1 IFNA2 KIT
36 pericoronitis 10.4 IL3 KIT KITLG
37 abdominal obesity-metabolic syndrome 10.4 JAK2 PDGFRA PDGFRB RUNX1 SETBP1
38 colorectal adenoma 10.4 FLT3 JAK2 PDGFRB RUNX1 SETBP1
39 circumscribed cutaneous aplasia of the vertex 10.4 CSF3 IFNA1 IFNA2 SETBP1
40 focal epilepsy 10.4 ABL1 BCR JAK2 PDGFRA PDGFRB
41 grix blankenship peterson syndrome 10.4 CSF2 CSF3 IL3
42 amblyopia 10.4 ABL1 BCR FLT3 JAK2 RUNX1
43 dupuytren contracture 10.4 BCR FLT3 KIT PDGFRB RUNX1
44 orbital margin, hypoplasia of 10.4 IFNA1 PDGFRA PDGFRB
45 extranodal nasal nk/t cell lymphoma 10.4 CSF3 KIT KITLG
46 intestinal impaction 10.4 IL3 JAK2 KITLG STAT5A
47 multifocal osteogenic sarcoma 10.4 KIT PDGFRA PDGFRB
48 dentinogenesis imperfecta, shields type ii 10.4 KIT KITLG PDGFRA
49 neuromyelitis optica 10.4 FLT3 IFNA2 JAK2 KIT
50 phosphoserine phosphatase deficiency 10.4 ABL1 BCR FLT3 IL3 RUNX1

Comorbidity relations with Leukemia, Chronic Myeloid, Somatic via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid, Somatic:



Diseases related to Leukemia, Chronic Myeloid, Somatic

Symptoms & Phenotypes for Leukemia, Chronic Myeloid, Somatic

Symptoms by clinical synopsis from OMIM:

608232

Clinical features from OMIM:

608232

Human phenotypes related to Leukemia, Chronic Myeloid, Somatic:

56 32 (show all 13)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Frequent (79-30%) HP:0012378
2 fever 56 32 Frequent (79-30%) HP:0001945
3 splenomegaly 56 32 Frequent (79-30%) HP:0001744
4 thrombocytopenia 56 32 Frequent (79-30%) HP:0001873
5 thrombocytosis 56 32 Frequent (79-30%) HP:0001894
6 leukocytosis 56 32 Frequent (79-30%) HP:0001974
7 poor appetite 56 32 Frequent (79-30%) HP:0004396
8 myeloproliferative disorder 56 32 Obligate (100%) HP:0005547
9 abnormality of basophils 56 32 Frequent (79-30%) HP:0001912
10 abnormality of blood and blood-forming tissues 56 Frequent (79-30%)
11 abnormality of granulocytes 56 Frequent (79-30%)
12 chronic myelogenous leukemia 32 HP:0005506
13 ph-positive acute lymphoblastic leukemia 32 HP:0004848

UMLS symptoms related to Leukemia, Chronic Myeloid, Somatic:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia, Chronic Myeloid, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 BCR
2 Decreased viability GR00173-A 10.56 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 10.56 ABL1 CRKL FLT3 PDGFRA PDGFRB KIT
4 Decreased viability GR00221-A-2 10.56 BCR ABL1 CRKL
5 Decreased viability GR00221-A-3 10.56 ABL1 PDGFRA PDGFRB
6 Decreased viability GR00221-A-4 10.56 BCR CRKL FLT3 PDGFRA PDGFRB
7 Decreased viability GR00301-A 10.56 BCR KIT
8 Decreased viability GR00342-S-1 10.56 ABL1 PDGFRB
9 Decreased viability GR00342-S-2 10.56 ABL1
10 Decreased viability GR00342-S-3 10.56 ABL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.3 ABL1 BCR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.3 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.3 ABL1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.3 LYN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.3 CSF3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.3 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.3 BCR SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.3 ABL1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.3 BCR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.3 STAT5A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.3 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.3 CRKL
23 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.3 ABL1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.3 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.3 KIT ABL1 SETBP1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.3 STAT5A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.3 CRKL
28 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.3 BCR SETBP1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.3 BCR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.3 SETBP1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.3 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.3 CRKL
33 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.3 STAT5A
34 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.3 SETBP1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.3 LYN SETBP1 STAT5A
36 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.3 SETBP1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.3 BCR
38 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.3 CRKL
39 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.3 LYN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.3 BCR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.3 BCR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.3 ABL1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.3 KIT ABL1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.3 LYN
45 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.3 KIT STAT5A
46 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.3 ABL1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.3 CSF3
48 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.3 ABL1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.3 LYN CRKL
50 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.3 CSF3
51 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.3 STAT5A
52 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.3 SETBP1
53 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.3 SETBP1
54 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.3 ABL1 LYN BCR CSF3
55 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.3 KIT ABL1 LYN BCR SETBP1 CRKL
56 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.3 KIT
57 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.3 KIT
58 Decreased substrate adherent cell growth GR00193-A-1 9.8 KIT
59 Decreased substrate adherent cell growth GR00193-A-2 9.8 ABL1 KIT
60 Decreased substrate adherent cell growth GR00193-A-4 9.8 ABL1 FLT3 KIT
61 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 KIT LYN
62 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 9.13 FLT3 KIT LYN

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid, Somatic:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.35 ABL1 BCR CRKL CSF2 CSF3 FLT3
2 homeostasis/metabolism MP:0005376 10.33 ABL1 BCR CSF2 FLT3 IRF8 JAK2
3 immune system MP:0005387 10.31 BCR CRKL CSF2 CSF3 FLT3 IRF8
4 cellular MP:0005384 10.3 ABL1 BCR CSF2 JAK2 KIT KITLG
5 growth/size/body region MP:0005378 10.27 ABL1 BCR CRKL CSF2 FLT3 JAK2
6 endocrine/exocrine gland MP:0005379 10.25 PDGFRB RUNX1 STAT5A ABL1 CRKL CSF2
7 mortality/aging MP:0010768 10.2 ABL1 BCR CRKL CSF2 FLT3 IRF8
8 embryo MP:0005380 10.18 ABL1 CRKL CSF2 JAK2 KIT KITLG
9 digestive/alimentary MP:0005381 10.14 ABL1 BCR KIT KITLG LYN PDGFRA
10 integument MP:0010771 10.14 CRKL CSF2 CSF3 JAK2 KIT KITLG
11 liver/biliary system MP:0005370 10.11 ABL1 BCR CRKL IRF8 JAK2 KIT
12 craniofacial MP:0005382 10.09 ABL1 CRKL CSF2 KIT KITLG PDGFRA
13 neoplasm MP:0002006 9.91 CRKL CSF2 FLT3 IRF8 JAK2 KIT
14 normal MP:0002873 9.81 KIT PDGFRA PDGFRB RUNX1 STAT5A ABL1
15 renal/urinary system MP:0005367 9.56 BCR CSF2 CSF3 KIT LYN PDGFRA
16 skeleton MP:0005390 9.32 ABL1 CRKL CSF2 FLT3 JAK2 KIT

Drugs & Therapeutics for Leukemia, Chronic Myeloid, Somatic

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bosulif 17 46 BOSUTINIB MONOHYDRATE Pfizer Approved September 2012
2
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
3
Gleevec 17 46 IMATINIB MESYLATE Novartis Approved May 2001
4
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
5
Sprycel 17 46 DASATINIB Bristol-Myers Squibb Approved June 2006
6
Synribo 17 46 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical Approved October 2012
7
Tasigna 17 46 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis Approved October 2007

Drugs for Leukemia, Chronic Myeloid, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
4
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
5
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
6
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
7 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
8 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1 123596
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
15 interferons Phase 4,Phase 3,Phase 2,Phase 1
16 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22
Lactitol Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
23 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1
24 tyrosine Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
25
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
26
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
27
Idarubicin Approved Phase 3,Phase 2,Phase 1 58957-92-9 42890
28
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
29
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
30
Iron Approved Phase 2, Phase 3, Phase 1, Early Phase 1 7439-89-6 23925
31
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
32
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Ofloxacin Approved Phase 3 82419-36-1 4583
35
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
36
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
37
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
38
Cyclosporine Approved, Investigational, Vet_approved Phase 2, Phase 3, Phase 1 79217-60-0, 59865-13-3 5284373 6435893
39
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
41
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
43
Peginterferon alfa-2b Approved Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
44
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
45
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
46
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
47
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
48
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
49
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
50
alemtuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 216503-57-0

Interventional clinical trials:

(show top 50) (show all 1461)
id Name Status NCT ID Phase
1 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
2 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
3 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4
4 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4
5 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4
6 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4
7 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4
8 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4
9 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4
10 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4
11 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4
12 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4
13 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4
14 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4
15 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4
16 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
17 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Recruiting NCT02228382 Phase 4
18 Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib Recruiting NCT02689440 Phase 4
19 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4
20 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Active, not recruiting NCT02204722 Phase 4
21 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4
22 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Not yet recruiting NCT02317159 Phase 4
23 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Not yet recruiting NCT02602314 Phase 4
24 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Not yet recruiting NCT02389920 Phase 4
25 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
26 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
27 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4
28 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4
29 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4
30 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3
31 Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Unknown status NCT00055874 Phase 3
32 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3
33 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3
34 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3
35 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
36 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3
37 The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML Unknown status NCT02204644 Phase 3
38 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3
39 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3
40 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
41 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
42 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
43 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3
44 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
45 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3
46 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3
47 Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Approved for marketing NCT00905593 Phase 3
48 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Completed NCT01254188 Phase 3
49 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase Completed NCT00451035 Phase 2, Phase 3
50 Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions Completed NCT02103322 Phase 2, Phase 3

Search NIH Clinical Center for Leukemia, Chronic Myeloid, Somatic

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Myeloid, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Myeloid, Somatic:
Hemacord
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Myeloid, Somatic:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myelogenous, chronic, bcr-abl positive

Genetic Tests for Leukemia, Chronic Myeloid, Somatic

Genetic tests related to Leukemia, Chronic Myeloid, Somatic:

id Genetic test Affiliating Genes
1 Chronic Myeloid Leukemia 29
2 Leukemia, Chronic Myeloid, Atypical 29
3 Chronic Myelogenous Leukemia 29

Anatomical Context for Leukemia, Chronic Myeloid, Somatic

MalaCards organs/tissues related to Leukemia, Chronic Myeloid, Somatic:

39
Myeloid, Bone, Bone Marrow, Spleen, Testes, Liver, Endothelial

Publications for Leukemia, Chronic Myeloid, Somatic

Variations for Leukemia, Chronic Myeloid, Somatic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid, Somatic:

66
id Symbol AA change Variation ID SNP ID
1 SETBP1 p.Asp868Asn VAR_063807 rs267607042
2 SETBP1 p.Gly870Ser VAR_063809 rs267607040
3 SETBP1 p.Ile871Thr VAR_063810 rs267607038
4 SETBP1 p.Glu858Lys VAR_069849

ClinVar genetic disease variations for Leukemia, Chronic Myeloid, Somatic:

6 (show all 32)
id Gene Variation Type Significance SNP ID Assembly Location
1 SETBP1 NM_015559.2(SETBP1): c.2608G> A (p.Gly870Ser) single nucleotide variant Pathogenic rs267607040 GRCh37 Chromosome 18, 42531913: 42531913
2 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh37 Chromosome 9, 133748283: 133748283
3 ABL1 NM_007313.2(ABL1): c.763G> A (p.Glu255Lys) single nucleotide variant Pathogenic/Likely pathogenic rs387906517 GRCh37 Chromosome 9, 133738306: 133738306
4 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh37 Chromosome 9, 133738357: 133738357
5 ABL1 NM_007313.2(ABL1): c.1109T> C (p.Met370Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913457 GRCh37 Chromosome 9, 133748391: 133748391
6 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
7 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
8 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
9 CSF3R NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile) single nucleotide variant Pathogenic/Likely pathogenic rs796065343 GRCh37 Chromosome 1, 36933434: 36933434
10 ABL1 NM_005157.5(ABL1): c.730A> G (p.Met244Val) single nucleotide variant Likely pathogenic rs121913456 GRCh37 Chromosome 9, 133738330: 133738330
11 ABL1 NM_005157.5(ABL1): c.742C> G (p.Leu248Val) single nucleotide variant Likely pathogenic rs121913455 GRCh37 Chromosome 9, 133738342: 133738342
12 ABL1 NM_005157.5(ABL1): c.749G> A (p.Gly250Glu) single nucleotide variant Likely pathogenic rs121913453 GRCh37 Chromosome 9, 133738349: 133738349
13 ABL1 NM_005157.5(ABL1): c.756G> C (p.Gln252His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
14 ABL1 NM_007313.2(ABL1): c.813G> T (p.Gln271His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
15 ABL1 NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe) single nucleotide variant Likely pathogenic rs121913460 GRCh37 Chromosome 9, 133738358: 133738358
16 ABL1 NM_007313.2(ABL1): c.820G> A (p.Glu274Lys) single nucleotide variant Likely pathogenic rs121913448 GRCh37 Chromosome 9, 133738363: 133738363
17 ABL1 NM_005157.5(ABL1): c.764A> T (p.Glu255Val) single nucleotide variant Likely pathogenic rs121913449 GRCh37 Chromosome 9, 133738364: 133738364
18 ABL1 NM_005157.5(ABL1): c.847T> G (p.Phe283Val) single nucleotide variant Likely pathogenic rs1057519758 GRCh37 Chromosome 9, 133747540: 133747540
19 ABL1 NM_005157.5(ABL1): c.951C> A (p.Phe317Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh38 Chromosome 9, 130872903: 130872903
20 ABL1 NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh37 Chromosome 9, 133748290: 133748290
21 ABL1 NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly) single nucleotide variant Likely pathogenic rs121913450 GRCh37 Chromosome 9, 133748403: 133748403
22 ABL1 NM_005157.5(ABL1): c.1075T> G (p.Phe359Val) single nucleotide variant Likely pathogenic rs121913452 GRCh37 Chromosome 9, 133748414: 133748414
23 ABL1 NM_005157.5(ABL1): c.1187A> G (p.His396Arg) single nucleotide variant Likely pathogenic rs121913454 GRCh37 Chromosome 9, 133750356: 133750356
24 ABL1 NM_007313.2(ABL1): c.952G> C (p.Val318Leu) single nucleotide variant Likely pathogenic rs1057519771 GRCh37 Chromosome 9, 133747588: 133747588
25 ABL1 NM_005157.5(ABL1): c.943A> G (p.Thr315Ala) single nucleotide variant Likely pathogenic rs1057519772 GRCh37 Chromosome 9, 133748282: 133748282
26 ABL1 NM_005157.5(ABL1): c.949T> A (p.Phe317Ile) single nucleotide variant Likely pathogenic rs1057519773 GRCh37 Chromosome 9, 133748288: 133748288
27 ABL1 NM_007313.2(ABL1): c.1006T> G (p.Phe336Val) single nucleotide variant Likely pathogenic rs1057519773 GRCh38 Chromosome 9, 130872901: 130872901
28 ABL1 NM_007313.2(ABL1): c.1007T> G (p.Phe336Cys) single nucleotide variant Likely pathogenic rs1057519774 GRCh37 Chromosome 9, 133748289: 133748289
29 ABL1 NM_007313.2(ABL1): c.1132T> A (p.Phe378Ile) single nucleotide variant Likely pathogenic rs121913452 GRCh37 Chromosome 9, 133748414: 133748414
30 ABL1 NM_005157.5(ABL1): c.1075T> C (p.Phe359Leu) single nucleotide variant Likely pathogenic rs121913452 GRCh37 Chromosome 9, 133748414: 133748414
31 ABL1 NM_005157.5(ABL1): c.1076T> G (p.Phe359Cys) single nucleotide variant Likely pathogenic rs1057519775 GRCh37 Chromosome 9, 133748415: 133748415
32 CSF3R NM_156039.3(CSF3R): c.1843A> G (p.Thr615Ala) single nucleotide variant Likely pathogenic rs1057519776 GRCh37 Chromosome 1, 36933444: 36933444

Copy number variations for Leukemia, Chronic Myeloid, Somatic from CNVD:

7 (show all 45)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37133 1 858000 52858291 Copy numbercopy numb erLOH Chronic myeloid leukemia
2 44672 10 61218526 61336824 Translate D10S170 Chronic myelogenous leukemia
3 56890 11 61840484 62345935 Loss Chronic myeloid leukemia
4 59436 11 75208816 75845444 Loss Chronic myeloid leukemia
5 78023 13 48911492 50087172 Loss Chronic myeloid leukemia
6 83260 14 19767470 106339477 Gain Chronic myeloid leukemia
7 84230 14 24600000 33300000 Deletion Chronic myeloid leukemia
8 99762 16 28519207 31440323 Loss Chronic myeloid leukemia
9 138867 2 172217486 173146666 Loss Chronic myeloid leukemia
10 143230 2 234301355 238853232 Loss Chronic myeloid leukemia
11 162523 22 21962191 22180167 Loss Chronic myeloid leukemia
12 162524 22 21962191 22410163 Loss Chronic myeloid leukemia
13 162525 22 21962191 23748456 Loss Chronic myeloid leukemia
14 162526 22 21963005 23840758 Loss Chronic myeloid leukemia
15 162527 22 21965685 22103948 Loss Chronic myeloid leukemia
16 162528 22 21965685 22211587 Loss Chronic myeloid leukemia
17 162529 22 21965685 22575018 Loss Chronic myeloid leukemia
18 162530 22 21965685 23038955 Loss Chronic myeloid leukemia
19 162531 22 21965685 23404027 Loss Chronic myeloid leukemia
20 162532 22 21965685 23779268 Loss Chronic myeloid leukemia
21 162533 22 21969649 23264408 Loss Chronic myeloid leukemia
22 162539 22 21996232 23317147 Loss Chronic myeloid leukemia
23 162540 22 22020300 22659711 Loss Chronic myeloid leukemia
24 162567 22 22184646 22476629 Loss Chronic myeloid leukemia
25 162599 22 22374488 22513875 Loss Chronic myeloid leukemia
26 162992 22 23595985 23627388 Copy number Chronic myeloid leukemia
27 227187 7 65425674 65447246 Copy number GUSB Chronic myeloid leukemia
28 229935 7 97199324 142723486 Loss Chronic myeloid leukemia
29 231976 8 109706119 120929916 Loss Chronic myeloid leukemia
30 239048 8 3687491 5908007 Loss Chronic myeloid leukemia
31 247260 9 129645960 132672275 Loss Chronic myeloid leukemia
32 247319 9 130014643 132618574 Loss Chronic myeloid leukemia
33 247584 9 130432414 131425779 Loss Chronic myeloid leukemia
34 247725 9 130855419 132584828 Loss Chronic myeloid leukemia
35 247730 9 130896183 132618574 Loss Chronic myeloid leukemia
36 247834 9 131532978 132607062 Loss Chronic myeloid leukemia
37 247856 9 131641050 132590178 Loss Chronic myeloid leukemia
38 247886 9 131997035 132590178 Loss Chronic myeloid leukemia
39 247924 9 132362204 132593161 Loss Chronic myeloid leukemia
40 247932 9 132430323 132610819 Loss Chronic myeloid leukemia
41 248025 9 132985174 134219212 Loss Chronic myeloid leukemia
42 248051 9 133107127 133390056 Loss Chronic myeloid leukemia
43 248180 9 133589267 133763060 Copy number ABL1 Chronic myeloid leukemia
44 250432 9 212399 32604310 Loss Chronic myeloid leukemia
45 251914 9 3330 20811568 Copy numbercopy numb erLOH Chronic myeloid leukemia

Expression for Leukemia, Chronic Myeloid, Somatic

Search GEO for disease gene expression data for Leukemia, Chronic Myeloid, Somatic.

Pathways for Leukemia, Chronic Myeloid, Somatic

Pathways related to Leukemia, Chronic Myeloid, Somatic according to KEGG:

37
id Name Kegg Source Accession
1 Chronic myeloid leukemia hsa05220

Pathways related to Leukemia, Chronic Myeloid, Somatic according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 ABL1 CRKL CSF2 CSF3 FLT3 IFNA1
2
Show member pathways
13.89 ABL1 CSF2 CSF3 FLT3 IL3 JAK2
3
Show member pathways
13.75 FLT3 IL3 JAK2 KIT KITLG LYN
4
Show member pathways
13.66 CSF2 CSF3 FLT3 IFNA1 IFNA2 IL3
5
Show member pathways
13.53 CRKL FLT3 IFNA1 IFNA2 IL3 JAK2
6
Show member pathways
13.52 ABL1 CSF2 IL3 JAK2 KIT KITLG
7
Show member pathways
13.41 CSF2 CSF3 FLT3 IL3 JAK2 KIT
8
Show member pathways
13.33 ABL1 CSF2 IFNA1 IFNA2 IL3 JAK2
9
Show member pathways
13.32 CSF2 CSF3 IL3 JAK2 KIT KITLG
10
Show member pathways
13.07 IL3 KIT KITLG LYN PDGFRA PDGFRB
11
Show member pathways
13.07 IL3 JAK2 KIT KITLG LYN PDGFRA
12
Show member pathways
12.94 CRKL CSF2 CSF3 FLT3 IFNA1 IFNA2
13
Show member pathways
12.92 CRKL JAK2 KIT KITLG LYN PDGFRA
14
Show member pathways
12.86 ABL1 IFNA1 IFNA2 IL3 PDGFRA
15
Show member pathways
12.75 ABL1 CRKL KIT KITLG PDGFRA PDGFRB
16
Show member pathways
12.74 KIT KITLG LYN PDGFRA PDGFRB
17 12.56 CSF3 IFNA1 IFNA2 IL3 JAK2 KIT
18
Show member pathways
12.54 CRKL CSF2 IFNA1 IFNA2 IL3
19 12.45 ABL1 BCR CRKL FLT3 KIT KITLG
20 12.43 CSF2 PDGFRA PDGFRB STAT5A
21
Show member pathways
12.42 KIT KITLG PDGFRA PDGFRB SLC22A1
22 12.41 IFNA1 IL3 IRF8 JAK2 KIT KITLG
23
Show member pathways
12.36 FLT3 KIT RUNX1 STAT5A
24
Show member pathways
12.34 FLT3 IL3 JAK2 STAT5A
25
Show member pathways
12.33 CRKL IFNA1 IFNA2 JAK2 STAT5A
26 12.25 CSF2 FLT3 IL3 RUNX1
27
Show member pathways
12.24 CSF2 CSF3 IFNA1 IFNA2 IL3 JAK2
28 12.21 ABL1 CRKL JAK2 STAT5A
29 12.19 ABL1 IFNA1 IFNA2 JAK2
30
Show member pathways
12.18 CRKL IL3 JAK2 KIT KITLG LYN
31
Show member pathways
12.17 CSF2 IL3 JAK2 LYN
32
Show member pathways
12.17 IFNA1 IFNA2 IL3 IRF8
33
Show member pathways
12.13 ABL1 BCR CRKL RUNX1 STAT5A
34 12.1 IL3 KITLG PDGFRB RUNX1
35
Show member pathways
12.1 CRKL JAK2 LYN STAT5A
36 12.02 CSF2 CSF3 FLT3 IFNA2 IL3 KIT
37 11.94 CSF2 CSF3 FLT3 IL3 KIT KITLG
38
Show member pathways
11.92 CRKL JAK2 LYN STAT5A
39
Show member pathways
11.88 IL3 JAK2 STAT5A
40
Show member pathways
11.87 CSF2 CSF3 JAK2
41 11.87 ABL1 JAK2 LYN STAT5A
42 11.82 CSF2 FLT3 IFNA2 IRF8 KIT
43
Show member pathways
11.81 FLT3 KIT PDGFRB
44 11.77 JAK2 LYN STAT5A
45
Show member pathways
11.77 ABL1 BCR KIT PDGFRA PDGFRB
46 11.76 CRKL IL3 KITLG PDGFRA PDGFRB
47 11.73 IFNA1 IFNA2 IL3 JAK2 STAT5A
48 11.71 FLT3 KIT PDGFRA PDGFRB
49 11.62 ABL1 LYN PDGFRB STAT5A
50 11.58 JAK2 LYN PDGFRB STAT5A

GO Terms for Leukemia, Chronic Myeloid, Somatic

Cellular components related to Leukemia, Chronic Myeloid, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.8 ABL1 JAK2 LYN

Biological processes related to Leukemia, Chronic Myeloid, Somatic according to GeneCards Suite gene sharing:

(show all 50)
id Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.98 IFNA1 IFNA2 JAK2 LYN
2 cellular response to lipopolysaccharide GO:0071222 9.97 ABL1 BCR CSF2 CSF3